GlassScriptPhysician profile
Tyra D Kane
NPI 1639102924
$4,331.31
in general payments reported to CMS, 2019-2025
34 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $862 · 2021: $788 · 2022: $776 · 2023: $155 · 2024: $436 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,005.46 | 2019-2022 | |
| Abbvie INC. | $587.04 | 2019-2025 | |
| Novo Nordisk INC | $390.51 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Allergan, INC. | $339.25 | 2019-2020 | |
| Astellas Pharma US INC | $305.25 | 2022-2025 | Veozah |
| Gilead Sciences, INC. | $192.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $167.14 | 2019-2022 | |
| Janssen Biotech, INC. | $142.59 | 2019-2021 | |
| Pfizer INC. | $130.88 | 2019-2024 | |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Medtronic, INC. | $116.81 | 2021-2023 | Intellis Adaptivestim |
| Intercept Pharmaceuticals, INC. | $79.00 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $76.59 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.13 | 2019-2022 | |
| Amgen INC. | $71.98 | 2022-2024 | Otezla, Repatha |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.99 | 2022-2024 | Mounjaro |
| Baxter Healthcare | $47.24 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $42.14 | 2022-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $42.05 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $39.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.04 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $30.54 | 2019-2021 | |
| Glaxosmithkline, LLC. | $30.15 | 2020-2022 | |
| Inspire Medical Systems, INC. | $27.46 | 2025 | Inspire |
| Abbott Laboratories | $24.70 | 2024 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $20.67 | 2020 | |
| Boston Scientific Corporation | $16.91 | 2022 | |
| Sanofi Pasteur INC. | $16.35 | 2020 | |
| Braintree Laboratories, INC. | $14.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2022 | |
| Currax Pharmaceuticals LLC | $14.23 | 2022 | |
| Amarin Pharma, INC. | $14.01 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.71 | 2022 | |
| Qol Medical, LLC | $9.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyra Kane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.